Does Cigna Cover NMN/NR (Nicotinamide Mononucleotide/Riboside)?

Understanding NMN and NR: What Are These NAD Precursors?

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme present in every living cell that declines with age. NAD+ is required for mitochondrial energy production, DNA repair, and sirtuin activation. The interest in supplementing these precursors has grown rapidly since preclinical work demonstrated that restoring NAD+ levels could reverse age-related metabolic dysfunction in mice.

NMN and NR are not the same molecule. NR (marketed under brand names like Tru Niagen) is a form of vitamin B3 that received FDA Generally Recognized as Safe (GRAS) status and is sold as a dietary supplement 1. NMN, on the other hand, was the subject of a controversial 2022 FDA determination that excluded it from dietary supplement marketing because it had been investigated as a drug candidate before being sold as a supplement 2. This regulatory split matters for insurance. Cigna, like most commercial insurers, draws a hard line between FDA-approved prescription medications (which enter formulary review) and supplements or compounded products (which generally do not).

The first randomized controlled trial of NMN in humans, published by Yoshino et al. in Science (2021, N=25 postmenopausal prediabetic women), showed that 250 mg/day of NMN for 10 weeks improved skeletal muscle insulin signaling and glucose uptake by approximately 25% compared to placebo 3. A separate 12-week RCT of NR (CHROMADEX-sponsored, N=40) demonstrated a sustained 40% increase in whole-blood NAD+ levels at 1,000 mg/day without serious adverse events 4.

These results are promising but small. No large Phase III trial has been completed for either compound.

Cigna's Default Coverage Policy for NMN and NR

Cigna commercial PPO and HMO plans exclude OTC dietary supplements from their pharmacy benefit. This means standalone NR products (Tru Niagen, Elysium Basis) are not reimbursable regardless of medical necessity documentation. The plan's Summary of Benefits and Coverage (SBC) typically states that "vitamins, minerals, and nutritional supplements" are member-responsibility expenses 5.

Compounded NMN or NAD+ formulations occupy a gray zone. Cigna does maintain a compounding benefit under select plans, and compounded NAD precursors prescribed by a licensed provider may be eligible for coverage with prior authorization (PA) plus precertification. The PA process requires the prescribing physician to submit documentation of a specific clinical indication (such as metabolic syndrome or documented NAD+ deficiency confirmed by laboratory testing) rather than a general "anti-aging" or "longevity" rationale 5.

Approval rates for compounded NAD precursor PAs at Cigna are not publicly reported. Anecdotal reports from prescribers suggest the approval rate runs between 15% and 30% on first submission, increasing to roughly 50% after a well-documented appeal. The Endocrine Society has not published formal clinical practice guidelines for NMN or NR supplementation as of May 2026 6, which makes building a guideline-backed PA argument difficult.

Prior Authorization Criteria and Documentation Requirements

Getting a Cigna PA approved for a compounded NAD precursor formulation requires specific clinical documentation. The process is rated as moderate difficulty by industry pharmacy benefit consultants, meaning it is neither automatic nor prohibitively complex.

Cigna's PA review team typically looks for three elements. First, a documented clinical diagnosis that is recognized by ICD-10 coding (metabolic syndrome E88.81, mitochondrial myopathy G71.3, or age-related NAD+ depletion if supported by laboratory evidence). Second, laboratory results showing reduced NAD+ or related biomarkers. Whole-blood NAD+ testing is offered by several CLIA-certified labs, though reference ranges are not yet standardized 7. Third, a letter of medical necessity from the prescribing physician explaining why FDA-approved alternatives (such as niacin or nicotinamide) are insufficient or contraindicated.

Turnaround time for standard PA decisions at Cigna is 5 to 15 business days for non-urgent requests. Expedited (urgent) reviews must be completed within 72 hours per federal parity requirements. Members can check PA status through the myCigna portal or by calling the number on their member ID card.

A common reason for PA denial is the lack of a specific, covered diagnosis. "Longevity optimization" and "anti-aging" are not billable ICD-10 codes. Clinicians who reframe the request around a measurable metabolic endpoint (insulin resistance, documented mitochondrial dysfunction) report higher success rates according to pharmacy benefit advocacy groups 8.

Cigna Formulary Placement: Where Do NMN and NR Sit?

Neither NMN nor NR appears on Cigna's standard commercial formulary. This is the core problem. Cigna organizes its formulary into tiers: Tier 1 (preferred generics), Tier 2 (non-preferred generics), Tier 3 (preferred brands), Tier 4 (non-preferred brands), and Tier 5 (specialty). Drugs must have FDA approval and an assigned National Drug Code (NDC) to enter formulary review.

NR supplements have NDCs assigned by the supplement manufacturer, but Cigna's pharmacy benefit manager (Express Scripts, for most Cigna commercial plans) excludes them from formulary consideration because they are classified as dietary supplements rather than prescription drugs 5. NMN lacks even this pathway following the FDA's 2022 reclassification.

Compounded formulations bypass the formulary entirely. They are adjudicated under the compounding benefit, which is a separate coverage channel with its own PA and quantity limit rules. Not all Cigna plans include a compounding benefit. Members should verify coverage by checking their plan's SBC or calling Express Scripts directly.

For comparison, prescription niacin (Niaspan) and prescription nicotinamide are on most Cigna formularies at Tier 1 or Tier 2 pricing. Niacin raises NAD+ levels modestly but carries flushing side effects and has fallen out of favor for cardiovascular indications after the AIM-HIGH trial (N=3,414) showed no incremental benefit when added to a statin 9.

Step Therapy Requirements at Cigna

Cigna does not have a formal step therapy protocol for NMN or NR because neither compound holds formulary status. Step therapy, by definition, requires a member to try and fail a lower-cost formulary drug before the plan covers a higher-tier alternative.

In practice, PA reviewers may informally apply step therapy logic. If a member requests coverage for a compounded NMN formulation, the reviewer might ask whether the patient first tried prescription niacin or nicotinamide (both of which raise NAD+ to some degree). Having documentation that the patient tried niacin 500 to 2,000 mg/day and experienced intolerable flushing, or tried extended-release niacin with inadequate NAD+ biomarker response, strengthens the PA case 9.

This is not a codified requirement. It is a pattern observed in PA denial letters and described by pharmacy benefit consultants who specialize in compounding coverage disputes.

How to Appeal a Cigna Denial for NMN or NR

Cigna provides a two-level internal appeal process followed by access to an external independent review organization (IRO). The steps are clearly defined under federal and state insurance regulations.

Level 1 internal appeal. Members or their physicians have 180 days from the denial date to submit a written appeal. Include: the original denial letter, updated clinical notes, laboratory evidence of NAD+ status or metabolic dysfunction, published literature supporting the compound's use for the documented diagnosis, and a revised letter of medical necessity. Cigna must issue a decision within 30 days for non-urgent cases 5.

Level 2 internal appeal. If Level 1 is upheld, a second internal review by a different clinical reviewer is available. The same 180-day filing window applies from the Level 1 decision date.

External IRO review. After exhausting both internal levels (or simultaneously in urgent situations), members can request an external review by a state-approved independent review organization. The external reviewer's decision is binding on Cigna. The Affordable Care Act guarantees this right for all non-grandfathered commercial plans 10.

Key tips for a successful appeal: reference specific published trials (Yoshino et al. 2021 3 is the most cited human NMN trial), include before-and-after NAD+ lab values if available, and frame the request around a recognized medical condition rather than wellness optimization.

Cash-Pay Pricing and Manufacturer Savings Options

Because most Cigna members will pay out of pocket for NMN or NR, understanding market pricing matters. The average cash-pay cost for a 30-day supply of a quality-tested NAD precursor runs approximately $80 per month, though prices range from $40 to $150 depending on brand, dose, and formulation 11.

NR products with third-party testing include Tru Niagen (300 mg NR per capsule, ~$50/month for 300 mg/day) and Elysium Basis (NR plus pterostilbene, ~$60/month). NMN products vary more widely in quality. A 2023 analysis of commercially available NMN supplements found that only 11 of 22 tested products contained within 10% of their labeled NMN content 11. Buying from brands that publish certificates of analysis (COA) with third-party verification is recommended.

There is no manufacturer savings card program equivalent to what exists for branded prescription drugs. NR and NMN manufacturers occasionally offer subscription discounts of 10% to 20%. Some compounding pharmacies that prepare NMN formulations offer cash-pay pricing between $100 and $200 per month, which is competitive with or lower than the compounding benefit copay on some high-deductible Cigna plans.

HSA and FSA accounts may cover NMN or NR if a licensed provider writes a letter of medical necessity linking the supplement to a diagnosed condition. IRS rules require the supplement to be used "to treat a specific medical condition" rather than for general health 12.

NMN vs. NR: Which Has Stronger Evidence for Insurance Justification?

From a coverage standpoint, NR has a slight advantage. It holds GRAS status, has a longer track record of human safety data, and is manufactured under more standardized conditions. The NIAGEN NR chloride form used in Tru Niagen has been the subject of multiple published human trials showing consistent 40% to 60% increases in whole-blood NAD+ 4.

NMN's human evidence is growing. Beyond the Yoshino trial 3, a 2022 randomized controlled trial (N=66 healthy middle-aged adults) published in Science reported that 12 weeks of NMN at 600 or 900 mg/day increased blood NAD+ levels in a dose-dependent manner and improved 6-minute walk distance by 30 to 50 meters compared to placebo 13. An additional trial in amateur runners (N=48) showed that NMN supplementation at 600 mg/day for 6 weeks improved aerobic capacity measured by ventilatory threshold 14.

Neither compound has the kind of large, multi-site Phase III evidence (500+ participants, 52+ week duration, FDA-accepted primary endpoints) that insurers typically require for formulary inclusion. The American Academy of Anti-Aging Medicine (A4M) has published position statements supporting NAD+ precursor research but stops short of recommending routine clinical use pending larger trials 6.

For members building a Cigna PA or appeal, citing the Yoshino 2021 and the 2022 dose-response trials together creates the strongest available evidence package. Pair these with individual lab results showing low baseline NAD+ and post-supplementation improvement.

Practical Steps for Cigna Members Seeking NAD Precursor Coverage

Start by confirming your specific plan's compounding benefit. Call the number on your Cigna member ID card and ask: "Does my plan include a compounding pharmacy benefit, and what is the PA process for a compounded NAD precursor?" Document the representative's name and reference number.

If your plan includes compounding coverage, ask your prescribing physician to submit a PA with ICD-10 coding for a recognized metabolic condition, laboratory documentation, a trial of niacin or nicotinamide (if tolerated), and citations from published NMN/NR human trials. Request the PA on a non-urgent basis first to allow the standard 5-to-15 day review window.

If coverage is denied, file a Level 1 appeal within 180 days. Include additional literature and a detailed letter of medical necessity. If Level 1 fails, proceed to Level 2 and then to external IRO review.

If all appeals are exhausted, cash-pay at $80/month through a reputable brand with third-party testing is the most accessible path. Use HSA/FSA funds with a provider's letter of medical necessity linking the supplement to a diagnosed condition to preserve the tax advantage.

The NAD+ precursor field is moving quickly. As larger human trials report results over the next two to three years, the probability of formal formulary inclusion at Cigna and other major insurers will increase. Members who document their clinical use now, with lab values and provider notes, will be better positioned if coverage policies change.